المعالجة قبل انتاج الحمض النووى الريبوزومى الرسول

Pre-mRNA is the initial RNA transcript produced directly from DNA transcription in eukaryotes. It contains both exons (coding sequences) and introns (non-coding sequences) and must undergo processing before becoming functional mature mRNA. This processing includes 5' capping, 3' polyadenylation, and splicing to remove introns and join exons together.

Pre-mRNA processing removes non-coding introns and adds protective modifications that stabilize the mRNA molecule. The 5' cap and 3' poly-A tail protect mRNA from degradation and facilitate its export from the nucleus. These modifications also enhance translation efficiency and allow for alternative splicing, enabling one gene to produce multiple protein variants.

The spliceosome is a ribonucleoprotein complex composed of small nuclear RNAs and proteins that catalyzes the removal of introns from pre-mRNA. It recognizes specific splice sites at intron boundaries and catalyzes two transesterification reactions that join exons together. This process is essential for generating mature mRNA that can be translated into protein.

The 5' cap is a 7-methylguanosine structure added to the beginning of pre-mRNA during transcription. It protects the mRNA from degradation by exonucleases and serves as a recognition signal for ribosomal binding during translation. The cap also facilitates mRNA export from the nucleus and enhances translation initiation efficiency.

The 3' poly-A tail is a string of approximately 200 adenine nucleotides added to the 3' end of pre-mRNA after cleavage. It protects mRNA from 3' exonuclease degradation, enhances translation efficiency, and facilitates mRNA export from the nucleus. The poly-A tail also influences mRNA localization and stability within the cell.

Alternative RNA splicing allows a single pre-mRNA to be processed in multiple ways by including or excluding different exons. This produces multiple mRNA variants from one gene, each encoding proteins with different structures and functions. Alternative splicing enables cells to generate proteomic diversity without expanding genome size, allowing regulated splicing of exons and introns to create tissue-specific or condition-specific protein isoforms.

Pre-mRNA splicing efficiency is regulated by splicing factors, including SR proteins and other regulatory proteins that bind to exonic and intronic sequences. Chromatin structure also influences splicing by affecting RNA polymerase II elongation rates and accessibility of splice sites. These regulatory mechanisms allow cells to control which exons are included in the final mRNA, enabling tissue-specific and developmentally regulated protein expression.